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with acute dengue of varying severity using multiparametric flowcytometry. We determined 33 if the properties of Tfhs were correlated with viraemia, disease severity, plasmablast responses 34 and DENV-specific serum antibody responses. We further evaluated the changes in 35 neutralizing antibodies (Neut50) with viraemia and clinical disease severity in a different 36 cohort of patients with acute secondary DENV1 (DF=12, DHF=10) and DENV2 infection 37 (DF=8, DHF=9). 38 39 Tfhs (especially those producing IL-21 and co-expressing PD-1 and ICOS) were found to be 40 significantly expanded (p<0.0001) and highly activated in patients with DHF compared to 41 those with DF. The frequency of Tfh cells significantly correlated with DENV-specific IgG, 42 NS1-specific antibodies and Neut50 antibody titres, which were also significantly higher in 43 patients with DHF. Although the Neut50 titres increased during the course of acute secondary 44 DENV infection, they showed differences based on serotype. For instance, the Neut50 titres 45 were significantly higher during the latter part of illness in patients with DF compared DHF in 46 DENV1 infection, while in DENV2, patients with DHF had significantly higher titres. The 47 viral loads during early illness did not correlate with the subsequent rise in the Neut50 antibody 48 titres during time point of illness. 49
Introduction 99
Dengue viral infections represent one of the most rapidly emerging mosquito borne viral 100 infections in the world, resulting in 390 million infections annually, with an estimated annual 101 global cost of $8.9 billion [1] [2] . The WHO has named dengue as one of the ten threats to 102 global health in 2019 [3] . Intense disease monitoring with meticulous fluid management is 103 currently the only management option, as specific treatments options are not yet available. The 104 only registered dengue vaccine, was shown to have poor efficacy against some DENV 105 serotypes and has a potential to increase the risk of severe disease in dengue seronegative 106 individuals [4] [5] [6] . Although infection with a particular serotype of the DENV is thought to 107 result in lifelong immunity, there have been instances where infection with the same serotype 108 occurs despite the presence of neutralizing antibodies specific for that serotype [7, 8] . In 109 addition, some individuals who had high neutralizing antibody titres to DENV2 following 110 vaccination, subsequently developed infection with the same serotype [9] . Therefore, as the 111 correlates of protection against the DENV are still not clear, it is essential to understand the 112 role of T cells and antibodies in the protection against dengue infection. 113
114
The role of both conventional CD4+ and CD8+ T cells in dengue has been well studied and 115 show they are highly activated, [10-13] and recent investigations have shown that T cells in 116 dengue are likely to have a protective role [10, 12] . However, apart from eliminating cells 117 infected by the DENV and production of antiviral cytokines, certain subsets of T cells such as 118 the follicular helper T cells (Tfhs) also determine the type and magnitude of development of 119 virus specific antibody responses. Tfh cells, which are located in the germinal centre, play a 120 crucial role in activating germinal centre B cells leading to activation, isotype switching and 121 production of long lasting neutralizing antibodies [14, 15] . Some Tfh cells are also found in 122 the peripheral circulation and are identified by the expression of CXCR5. They also upregulate 123 6 PD-1, ICOS, Bcl-6, CD40 and produce IL-21, which are important for the activation of 124 germinal centre B cells [15] . It was recently shown that Tfh cells are highly activated in acute 125 dengue and also correlated with the frequency of plasmablasts [16] . The Tfh cells were also 126 shown to be able to produce IL-21 and IFNγ upon stimulation with DENV peptides, suggesting 127 that they were capable of providing B cell help, which is largely dependent on production of 128 IL-21 [17] . Therefore, increase in frequency and activation of Tfh cells could lead to higher 129 DENV specific antibody levels which may lead to protection, or possibly disease enhancement 130 [18, 19] . In order to further understand the pathogenesis of acute dengue and the constituents 131 
Results

171
Of the 40 patients included in the study to investigate the functionality and phenotype of Tfh 172 cells, the mean duration of illness at the time of recruitment was 7.1 (SD  1.9) days. Their 173 mean age was 35.98 years (SD  12.3). 18 patients had DF and 22 had DHF and all these 174 patients had a similar duration of illness. One of the patients with DHF developed shock. Mild 175 bleeding manifestations such as epistaxis and gum bleeds were seen in five patients. All the 176 samples were obtained from patients with DHF and DF at the same time (mean day of illness 177 7.1) and therefore, samples were obtained from those with DHF while they were in the critical 178 phase. All patients with DF and DHF were followed throughout the illness and none of the 179 patients with DF later developed fluid leakage and progressed to develop DHF. The clinical 180 and laboratory features of these patients is described in Supplementary The frequency of Tfhs in patients with acute illness (median = 4.21%, IQR = 3.49 to 5.69 of 196 CD4+ T cells) was significantly higher (p<0.0001) when compared to the frequencies in 197 healthy individuals (median = 2.13%, IQR = 1.10 to 2.82 of CD4+ T cells). The frequency of 198 Tfhs was also significantly higher (p<0.0001) in patients with DHF (median = 5.51%, IQR = 199 4.84 to 5.97 of CD4+ T cells) than in patients with DF (median = 3.59%, IQR = 2.99-3.95 of 200 CD4+ T cells). In addition, a significant expansion (p = 0.001) was observed in patients with 201 secondary dengue infection (median = 5.33%, IQR = 2.70 to 5.92 of CD4+ T cells) compared 202 to those with primary dengue infection (median = 3.67%, IQR = 3.01 to 3.90 of CD4+ T cells) 203 ( Fig 2) . 9 patients with DF had a primary infection, while 9 had a secondary dengue infection. 204
There was no difference in the Tfh cell frequency in those with primary or secondary dengue 205 infection, who had DF (p = 0.66). Furthermore, 4 patients with DHF had a primary infection, 206 while 18 had a secondary dengue infection. In patients who had DHF, the frequency of Tfhs 207 was significantly higher (p = 0.03) in those with secondary dengue infection (median = 5.64%, 208 IQR = 5.28 to 6.06 of CD4+ T cells) compared to those with primary dengue infection (median 209 = 3.40%, IQR = 3.08 to 5.35 of CD4+ T cells). Therefore, in order to investigate the cytokine production potential of Tfhs in acute dengue, we 237 sought to determine IL-21 production by the Tfhs in patients with acute dengue ex vivo. The 238 frequency of IL-21 producing Tfhs were highly significant (p<0.0001) in patients with acute 239 dengue (median = 3.62%, IQR = 2.95 to 4.67 CD4+CXCR5+ T cells) when compared with 240 healthy individuals (median = 0.19%, IQR = 0.00 to 1.24 CD4+CXCR5+ T cells), where hardly 241 any cytokine production was observed (Fig 3d) . The frequency of IL-21 producing Tfhs were 242 also significantly higher (p<0.0001) in patients with DHF (median = 4.41%, IQR = 3.63 to 243 5.10 CD4+CXCR5+ T cells) compared to those with DF (median = 2.96%, IQR = 2.63 to 3.43 244 CD4+CXCR5+ T cells) (Fig 3d) . 245
As the frequency of Tfhs were assessed in the acute phase, we proceed to investigate the 246 phenotype and functionality of these cells in the convalescent period (21 to 30 days since onset 247 of illness) in 14/40 in this cohort. Interestingly, the frequency of Tfhs was significantly higher 248 (p = 0.0002) during the convalescent phase in these patients (median = 7.74%, IQR = 5.70 to 249 8.53 of CD4+ T cells) compared to the frequencies in acute infection (median = 5.60%, IQR = 250 3.81-5.98) ( Fig. 3e ). Furthermore, the frequency of IL-21 producing Tfhs was significantly 251 higher (p = 0.0001) during convalescent phase (median = 27.15%, IQR = 19.97 to 32.52 252 The frequency of Tfhs inversely correlated with the viral loads (Spearman r = -0.63, p<0.0001) 261 of patients with acute dengue (Table 1 ), suggesting that Tfh expansion was associated with 262 resolution of viraemia. Although a significant inverse correlation was seen with the frequency 263 of IL-21 producing Tfhs and the viral loads (Spearman's r = -0.57, p = 0.0002) (Table1), no 264 correlation was observed between PD1 + ICOS + , PD1 + ICOS -, PD1 -ICOS + subsets of Tfh cells. 265
The frequency of Tfhs showed an inverse correlation with platelet counts in patients with acute 266 dengue infection (Spearman r = -0.42, p = 0.008). However, the platelet counts did not correlate 267 with the frequency of IL-21 producing Tfhs (Spearman r = -0.31, p = 0.058). 268 269 compared to healthy individuals (median = 0.87, IQR = 0.40 to 1.50 of total B cells) (Fig 6a) . 284
The frequencies of plasmablasts associated with clinical disease severity as they were 285 significantly higher (p<0.0001) in patients with DHF (median = 39.23, IQR = 30.47 to 48.26 286 of total B cells) when compared to those with DF (median = 26.47, IQR = 20.54 to 29.72 of 287 total of B cells) (Fig 6a) . The frequency of plasmablasts was also significantly higher (p=0.03) 288 in patients with secondary dengue infections (median = 34.51, IQR = 29.87 to 44.83 of B the 289 total B cells) to those with primary infections (median = 26.98%, IQR = 22.19 to 35.70 of the 290 total B cells) (Fig 6a) . 291
292
The frequency of plasmablasts significantly and positively correlated with the frequency of the 293 total Tfh cells (Spearman R=0.91, p<0.0001) (Fig 6b) . Although the frequency of plasmablasts 294 correlated with Tfh cells expressing PD1+ICOS+ (Spearman r=0.37, p=0.02) and with 295 PD1+ICOS-(Spearman r = 0.34, p=0.03) the greatest correlation was observed with Tfh cells 296 producing IL-21 (Spearman r = 0.78, p<0.0001) (Fig 6c) . A significant inverse correlation was 297 seen between the frequency of plasmablasts and the viral loads (Spearman r = -0.55, p = 298 0.0004) as well as with the lowest platelet count in the patients (Spearman r = -0.38, p = 0.01) 299 (Table 1) . 300
301
As with the frequency of Tfhs, we also determined the frequency of plasmablasts in the 302 convalescent phase in 14/40 patients in this cohort. The frequency of plasmablasts was 303 significantly higher (p = 0.0001) in convalescent phase (median = 44.95%, IQR = 36.84 to 304 51.10 of total B cells) than in the acute infection (median = 35.48%, IQR = 29.50 to 45.13 of 305 total B cells) ( Fig. 5 and 6d ). Similar to the observations in the acute phase of illness, the 306 frequency of plasmablasts significantly correlated with the frequency of IL-21 secreting Tfhs 307 in the convalescent phase (Spearman r = 0.92, p<0.0001) (Fig. 6e) . 308 309 Association of Tfhs and plasmablasts with DENV envelope protein specific antibody responses 310
The majority of the plasmablast response was found to be specific for the DENV in acute 311 dengue, predominantly comprising IgG secreting cells [22] . However, in a previous study no 312 association was seen between the frequency of plasmablasts and DENV-specific neutralizing 313 antibody titres (Neut50) [23] . Therefore, in order to study the relationship between Tfhs, 314 plasmablasts and DENV specific antibodies we investigated the association of Neut50, total 315 DENV antibodies and also DENV NS1 specific antibodies in this cohort of patients. = 0.79 to 29.62). We detected no significant correlation between DENV-specific IgM antibody 325 titres and frequency of Tfhs in patients with DF (Spearman r = 0.15, p = 0.54) and DHF 326 (Spearman r = 0.25, p = 0.24) ( Table 1) . As observed with Tfh cells, DENV-specific IgM 327 antibody titres did not correlate with the frequency of plasmablasts in patients with DF 328 (Spearman r = 0.27, p = 0.26) or in DHF (Spearman r = 0.21, p = 0.34) ( Table 1) . 329
330
The DENV-specific IgG titres also did not correlate with the frequency of Tfhs in patients with 331 DF (Spearman's r = 0.08, p = 0.73), but a significant correlation was seen in patients with DHF 332 (Spearman's r = 0.43, p = 0.04) (Table 1) . Similar findings were observed with plasmablasts 333 with no significant correlation between DENV-specific IgG titres in DF patients (Spearman r 334 = 0.18, P = 0.45) and significant correlation in patients with DHF (Spearman r = 0.48, p = 0.02) 335 (Table 1) . Furthermore, a significant correlation was detected between DENV-specific IgG 336 antibody titres and frequency of IL-21 producing Tfhs in patients with acute dengue (Spearman 337 r = 0.39, p = 0.01). 338 339 Association of Tfhs and plasmablasts with DENV NS1-specific antibody responses 340
Although the majority of DENV specific antibodies are specific to the DENV envelope protein, 341 27% of the DENV antibody repertoire has shown to be specific to DENV NS1 protein [29] . 342 Therefore, we measured DENV2 specific NS1 antibodies using an in-house ELISA as 343 described before [18] . As observed earlier, NS1-antibody levels were significantly higher in 344 patients with DHF (median 1.7, IQR 0.76 to 2.3 OD values) compared to those with DF 345 (median 0.56, IQR 0.23 to 1.4 OD values). We observed a significant correlation between NS1 346 antibody levels and frequencies of only IL-21 producing Tfh cells in DF (Spearman r = 0.48, 347 p = 0.04) but not in patients with DHF (Spearman r = 0.05, p = 0.81). However, a significant 348 correlation was not observed between NS1 antibody levels and frequencies of Tfh cells in 349 patients with DF (Spearman r = 0.23, p = 0.35) and DHF (Spearman r = 0.32, p = 0.14). 350
Similarly, we did not observe a significant correlation between NS1 antibody levels and 351 frequencies of plasmablasts in both DF (Spearman r = 0.44, p = 0.06) and in DHF (Spearman 352 r = 0.29, p = 0.18) ( Table 1) 0.48, p = 0.002). However, as the Panbio ELISA measured all DENV envelope specific 360 antibodies and not necessarily neutralizing antibodies, which are thought in some studies to 361 associate with protection, we then proceeded to determine association of neutralizing 362 antibodies specific to the infecting DENV serotype (DENV2) with the frequency of Tfhs and 363 plasmablasts. The Neut50 titres were significantly higher (p = 0.006) in patients with DHF 364 (median = 35821, IQR = 16,393 to 91,086) than in the patients with DF (median = 5314, IQR 365 = 2586 to 12,343). Although there was no significant correlation in Neut50 titres with the 366 frequency of Tfhs in patients with DF (Spearman r = 0.30, p = 0.21), a significant correlation 367 was detected between Neut50 titres and the frequency of Tfhs in patients with DHF 368 (Spearman's r = 0.80, p<0.0001) ( Table 1) . We observed the same relationship with the 369 frequency of plasmablasts. i.e. there was no significant correlation between Neut50 titres and 370 the frequency of plasmablasts in patients with DF (Spearman r = 0.42, p = 0.08) but in patients 371 with DHF (Spearman r = 0.61, p = 0.002) (Table 1) . Interestingly, in this cohort of patients 372 who all had a DENV2 infection, Neut50 titres only inversely correlated with the viral loads in 373 patients with DF (Spearman = -0.75, p = 0.0003) and not in those with DHF (Spearman's r = -374 0.26, p=0.23) (Fig 7a and 7b) . 375
376
The Neut50 titres were measured in the convalescent phase (day 21 to 30 since onset of illness) 377 in 14/40 patients with acute dengue, and the Neut50 titres were 10 fold higher (p = 0.0002) in 378 the convalescent phase (median 41,432, IQR=20,609 to 97,105 Neut50 titres) when compared 379 to the acute phase (median 4416, IQR 2,220 to 9,777 Neut50 titres) (Fig 7c) . The Neut50 380 antibody titres showed a significant correlation with the IL-21 producing Tfh cells (Spearman 381 r=0.73, p=0.004) and plasmablasts (Spearman r = 0.85, p=0.0002) but not with the total Tfh 382 cells (Spearman r = 0.06, p=0.82). 383 384 385 Kinetics of neutralizing antibody production in patients with varying severity of acute DENV1 386 and DENV2 infection 387
The above data show that Neut50 antibody titres significantly correlated with the frequency of 388 Tfh cells and plasmablasts in patients with DHF but not in those with DF and also inversely 389 correlated with the viral loads only in patients with DF. Although a Neut50 antibody titre of 390 1:10 is considered protective in some studies [30, 31] , some individuals high neutralizing 391
antibodies for a particular DENV serotype later went on to develop DHF when infected with 392 that particular serotype [32] . Furthermore, those who were found to have high Neut50 titres to 393 DENV2 in phase 2b and 3 dengue vaccine trials, were later found to be infected with the same 394 serotype when naturally exposed to the virus [33, 34] . Since the association of Neut50 titres 395 with clinical disease severity has not been assessed, we sought to investigate the changes in the 396 Neut50 titres throughout the course of illness in patients with an acute DENV1 or an acute 397 DENV2 infection. 398
399
As the Neut50 titres are likely to be different in those with primary and secondary dengue 400 longitudinally, in order to compare disease severity, we investigated the kinetics of Neut50 401 titres in a cohort of patients with secondary dengue (this is a different cohort that the patients 402 recruited for the Tfh studies). We studied the kinetics of the Neut50 titres in 40 patients with 403 varying severity of acute DENV-1 infection (DF = 12, DHF = 10) and DENV-2 infection (DF 404 = 8, DHF = 9) throughout the course of illness. Tthe first sample was obtained before any of 405 the patients proceeded to develop either DHF or DF. 406
407
We found that the Neut50 titres of those with acute secondary DF and DHF in both DENV1 408 and DENV2 infection were similar in the febrile phase before the onset of the plasma leakage 409 in patients with DHF (Fig 8a and 8b) . While the Neut50 titres exponentially increased in 410 patients with DF in acute secondary DENV1 infection, the opposite was observed in acute 411 secondary DENV2 infection. However, there was no significant difference in the viral loads in 412 patients with DF and DHF at any time point in the illness in acute secondary DENV1 infection 413 (Fig 8c) or in acute secondary DENV2 infection (Fig 8d) . The viral loads at the beginning of 414 the illness did not correlate with the Neut50 titres seen in the course of illness in patients with 415 producing Tfh cells further expanded in the convalescent phase along with plasmablasts, PD-447 1 expressing Tfhs cells significantly decreased suggesting that although the Tfh cells were 448 functional, they were less activated during the convalescent phase. Production of neutralising 449 antibodies too appear to continue after the acute phase (day 6 to 8 measured in this study) as 450 the Neut50 titres were 10 times higher in the convalescent phase compared to the values in the 451 acute phase. The Neut50 titres in the convalescent phase only correlated with the IL-21 452 producing Tfh cells, suggesting that this functional subset of Tfh cells is likely to be important 453 to drive high titres of long-lasting neutralising antibody titres. 454
455
The total population of Tfh cells and plasmablasts significantly correlated with Neut50 456 antibody titres and DENV-specific IgG antibodies, indicating their importance in driving 457 pathogen specific antibody responses during acute infection. Therefore, DENV specific-IgG, 458
Neut50 titres and NS1-antibody levels were significantly higher in those with DHF compared 459 to those with DF, probably due to increased numbers of plasmablasts producing higher levels 460 of DENV-specific antibodies. The frequency of Tfh cells, plasmablasts, DENV specific IgG 461 and Neut50 titres all inversely correlated with the viral loads, which suggest that they are likely 462 to be important in the control of the virus. The Neut50 antibody titres were significantly higher 463 in patients with DHF in the first cohort of patients infected with DENV2, which could be 464 suggesting that increased viral loads in patients with DHF lead to increased expansion of Tfh 465 cells and thus plasmablasts, resulting in higher Neut50 titres. However, we did not observe 466 higher viral loads in patients with DHF compared to those with DF, in this cohort of 40 patients, 467 whom we studied the Tfh, plasmablast and antibody responses. Since blood samples to study 468 these responses were obtained on a mean duration of illness of day 7.1, we would have missed 469 the early events that led to rise in the Neut50 titres in those with DHF compared to those with 470 DF. In addition, although we did not observe differences in viral loads in patients with DHF 471 compared to DF on day 6-8 of illness, it is possible that patients with high viral loads early in 472 illness, subsequently progressed to develop DHF and also these higher early viral loads resulted 473 in higher Neut50 titres in patients with DHF at a later time point in illness. 474
475
In order to address this question, we studied the kinetics of viral loads, Neut50 assays during 476 the febrile phase in a different cohort of patients with acute secondary infection due to DENV1 477 and DENV2. We chose patients with a secondary dengue infection, as it would be unsuitable 478 to compare antibody and viral loads in a cohort of patients with both primary and secondary 479 dengue infection. We also chose patient cohorts infected with 2 different types of virus 480 serotypes (DENV1 and DENV2) to better understand the changes in antibody and viral loads 481 based on DENV serotype. Our data showed that there was no difference in the viral loads in 482 patients with acute secondary DENV1 or DENV2 infection during the febrile phase, before 483 any of the patients progressed to develop vascular leak and thus DHF. In addition, there was 484 no difference in the viral loads throughout the illness in patients with DHF or DF due to 485 infection with either viral serotype. However, in both DENV1 and DENV2 infections, while 486 the viral loads continued to decline during the illness, the Neut50 titres rose. 487
488
During the febrile phase of illness again no difference was seen in the infecting viral specific 489
Neut50 titres in patients with either DENV1 or DENV2 infection who proceeded to develop 490 either DF or DHF. Therefore, the Neut50 titres at the beginning of illness, does not appear to 491 associate with subsequent clinical disease severity. Interestingly, in DENV1 infection the 492 Neut50 antibody titres significantly rose in those with DF compared to those with DHF 493 throughout the course of illness, whereas the opposite was seen in DENV2 infection (Neut50 494 titres rose higher in DHF>DF). This rise in the Neut50 titres throughout the illness was not 495 associated with the viral loads seen in early illness in either DF or DHF patients with DENV1 496 and DENV2. Therefore, these data show that the degree of viraemia during early illness was 497 not associated with the degree of subsequent rise in Neuto50 antibody titres. In addition, the 498 rise in neutralizing antibody titres does not appear to associate with clinical disease severity 499 but appears to be very different between DENV1 and DENV2. Previous studies have also 500 shown that the degree and duration of viraemia varied between DENV serotypes and there 501 were no differences in the degree of viraemia and kinetics between patients with DF and DHF 502 [35] [36] [37] . Collectively, these data show that the rise in the Neut50 antibody titres did not depend 503 on the extent of viraemia; Neut50 titres in the febrile phases in both acute secondary DENV1 504 and DENV2 were similar in patients who subsequently progressed to develop either DF or 505 DHF. 506
507
Although high Neut50 titres are considered to be protective against the infection with the 508 DENV, some individuals with high neutralizing antibodies for a particular DENV serotype 509 later went on to develop DHF when infected with that particular serotype [32] . In this study 510 too, patients who later progressed to develop DHF had similar Neut50 antibody titres as 511 patients who developed DF. Indeed, in a dengue vaccine trial, individuals with high 512 neutralizing antibody titres to certain DENV virus serotypes, were not protected with infection 513 with those serotypes, questioning the Neut50 antibody titres that associate with protection [9, 514 33]. Therefore, Neut50 antibody titres during the febrile phase measured by in vitro assays do 515 not appear to reflect a good correlate of in vivo protection. 516
517
In summary, the Tfhs appear to significantly expand in acute dengue, which associated with 518 clinical disease severity and plasmablast expansion. This increase in frequency also correlated 519 with DENV-specific IgG, Neut50 antibody titres and with NS1-specific antibody titres. Since 520 evaluation of Neut50 antibody titres in the febrile phase (before patients developed wither DF 521 or DHF) did not appear to associate with clinical disease severity or the degree of viraemia, 522 neutralizing titres alone do not appear to determine protection against severe clinical disease. In order to investigate the evolution of the Neut50 titres throughout the course of illness and to 556 determine if it associated with clinical disease severity and the degree of viraemia, we recruited 557 a different cohort of 39 patients with acute secondary DENV1 infection (n=22) and with acute 558 secondary DENV2 infection (n=17 ), Of those with acute secondary DENV1 infection, 12 559 patients had DF and 10 patients had DHF. Of those with acute secondary DENV2 infection, 8 560 patients had DF and 9 patients had DHF. They were recruited early during the course of illness, 561 before any of the patients had gone in the vascular leakage (critical phase). Therefore, by 562 obtaining daily blood samples in this cohort of patients, we could study the changes in the 563 In order to quantify viruses, standard curves of DENV serotypes were generated as previously 581 described by Fernando, S. et.al[38] . 
